To date, several radiolabeled GRPR-targeting ligands (i.e., AMBA, RM2, and NeoBOMB1), based on the amphibian GRP analog bombesin, have been introduced into the clinic for cancer diagnosis and radioligand therapy [11,12,13,14,15,16]. The gene discussed is GRPR; the disease is cancer.